Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
USP3 antisense RNA 1 (USP3-AS1)
- Target
- USP3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01
Overview
USP3 antisense RNA 1 (USP3-AS1) is a long non-coding RNA transcribed antisense to the USP3 gene, involved in the regulation of gene expression at multiple levels[2][3]. It functions predominantly by post-transcriptional and post-translational mechanisms, influencing protein stability (notably MYC), thereby promoting glycolysis and cell proliferation in cancer[6]. Antisense RNAs like USP3-AS1 are crucial in transcriptional interference, chromatin remodeling, and competitive endogenous RNA networks. In clinical contexts, USP3-AS1 is implicated in tumorigenesis and metabolic rewiring, especially in colorectal and potentially other cancers, making it a therapeutic target and biomarker candidate for cancer diagnostics and gene modulation therapies[6]. However, as a non-coding RNA, it is not a traditional drug target like receptors or enzymes, requiring nucleic acid-based therapeutic approaches.
- Other names
- USP3-AS1
02
Mechanism of action
Inhibition or silencing via antisense oligonucleotides (ASO) could cause RNA degradation (e.g., RNase H-mediated); Targeted modulation may alter gene regulatory networks through ceRNA (competitive endogenous RNA) mechanisms
03
Biological functions
Regulation of gene expression (by modulating transcription and RNA stability)Post-transcriptional modification (affecting stability of proteins such as MYC)Promotes glycolysis via post-translational mechanismMay function in cellular proliferation and apoptosis (especially in cancer contexts)
04
Disease associations
Cancer (regulation of oncogenes such as MYC, evidence in colorectal cancer organoid models)Other disease roles: Not well characterized beyond cancer
05
Safety considerations
Safety and off-target effects for antisense therapies would be a major consideration, as manipulation of lncRNAs may have broad regulatory consequencesPotential for unintended effects on sense gene (USP3) and related pathways
06
Interacting drugs
None identified in current literature (no small molecules or biologics known to target USP3-AS1 directly; interventions would likely be nucleic acid-based, e.g., antisense oligonucleotides)
07
Biomarkers
USP3-AS1 expression is elevated in certain cancers and may serve as a candidate biomarker for malignant transformation, prognosis, or MYC activityMay be a biomarker for metabolic reprogramming (glycolysis) in tumor cells
Beyond the preview
Go deeper on USP3 antisense RNA 1 (USP3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP3 antisense RNA 1 (USP3-AS1).